down arrow

Medtronic Plc

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IE00BTN1Y115
USD
101.99
-0.04 (-0.04%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

101.88102.75

52 Week

79.29106.33
Valuation
Technical
Day's Volume

CASH

1.54 M

Shareholding (Apr 2025)

FII

19.93%

Held by 526 FIIs

DII

45.9%

Held by 150 DIIs

Promoter

0.09%

How big is Medtronic Plc?

22-Jun-2025

As of Jun 18, Medtronic Plc has a market capitalization of $110.52 billion, with net sales of $33.54 billion and a net profit of $4.69 billion over the latest four quarters. The company reported shareholder's funds of $48.02 billion and total assets of $91.68 billion as of Apr 25.

Market Cap: As of Jun 18, Medtronic Plc has a market capitalization of 110,516.77 million, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Medtronic Plc reported net sales of 33,537.00 million and a net profit of 4,690.00 million.<BR><BR>Balance Sheet Snapshot: As of Apr 25, the company reported shareholder's funds of 48,024.00 million and total assets of 91,680.00 million.

Read More

What does Medtronic Plc do?

22-Jun-2025

Medtronic Plc is a large-cap medical technology and services company with recent net sales of $8.93 billion and a net profit of $1.06 billion. Key metrics include a P/E ratio of 21.00 and a dividend yield of 3.34%.

Overview:<BR>Medtronic Plc is a medical technology and services company operating in the Pharmaceuticals & Biotechnology industry, with a market cap in the large-cap bracket.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 8,927 Million (Quarterly Results - Apr 2025) <BR>Most recent Net Profit: 1,061 Million (Quarterly Results - Apr 2025) <BR>Market cap: USD 110,516.77 Million (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 21.00 <BR>Dividend Yield: 3.34% <BR>Debt Equity: 0.41 <BR>Return on Equity: 11.03% <BR>Price to Book: 2.30<BR><BR>Contact Details:<BR>Address: 20 On Hatch, Hatch Street Lower, DUBLIN None : 2 <BR>Tel: ['353 1 4381700', '1 763 5052692'] <BR>Website: http://www.medtronic.com/

Read More

Who are in the management team of Medtronic Plc?

22-Jun-2025

As of March 2022, Medtronic Plc's management team is led by Mr. Geoffrey Martha, who is the Executive Chairman, President, and CEO. The Board of Directors includes independent members such as Mr. Richard Anderson, Mr. Craig Arnold, Mr. Scott Donnelly, Ms. Andrea Goldsmith, and Mr. Randall Hogan.

As of March 2022, the management team of Medtronic Plc includes Mr. Geoffrey Martha, who serves as the Executive Chairman of the Board, President, and Chief Executive Officer. Additionally, the Board of Directors features several independent directors: Mr. Richard Anderson, Mr. Craig Arnold, Mr. Scott Donnelly, Ms. Andrea Goldsmith, and Mr. Randall Hogan.

Read More

Is Medtronic Plc overvalued or undervalued?

20-Sep-2025

As of August 19, 2025, Medtronic Plc is fairly valued with a P/E ratio of 21, an EV to EBITDA of 15.42, and a PEG ratio of 1.00, showing competitive positioning against peers, while achieving a YTD return of 19.67%, outperforming the S&P 500's 12.22%, but underperforming over five years with a return of -11.16% compared to the S&P 500's 96.61%.

As of 19 August 2025, the valuation grade for Medtronic Plc has moved from attractive to fair, indicating a shift in its perceived value. Based on the current metrics, the company appears to be fairly valued. The key ratios include a P/E ratio of 21, an EV to EBITDA of 15.42, and a PEG ratio of 1.00, which suggest that the stock is priced in line with its earnings growth potential.<BR><BR>In comparison to its peers, Medtronic Plc's P/E ratio of 21.47 is higher than Abbott Laboratories' 18.36 but lower than Thermo Fisher Scientific's 30.06, indicating a competitive positioning within the industry. Despite its fair valuation, Medtronic's recent stock performance shows a YTD return of 19.67%, outperforming the S&P 500's 12.22%, although it lags behind the index over longer periods, particularly with a 5Y return of -11.16% compared to the S&P 500's 96.61%.

Read More

Is Medtronic Plc technically bullish or bearish?

28-Oct-2025

As of October 24, 2025, Medtronic Plc's technical trend is mildly bullish, supported by positive MACD and moving averages, but recent performance shows underperformance against the S&P 500, suggesting caution despite year-to-date outperformance.

As of 24 October 2025, the technical trend for Medtronic Plc has changed from bullish to mildly bullish. The weekly and monthly MACD indicators are bullish, while the Bollinger Bands show a mildly bullish stance in both time frames. The daily moving averages also indicate a mildly bullish trend. However, the Dow Theory presents a mixed view with a mildly bearish signal on the weekly chart and a mildly bullish signal on the monthly chart. <BR><BR>In terms of performance, Medtronic has underperformed the S&P 500 over the past week and month, with returns of -2.20% and -2.16% respectively, compared to the S&P 500's gains of 1.92% and 2.32%. However, year-to-date, Medtronic has outperformed the S&P 500 with a return of 17.26% versus 15.47%. Overall, the technical stance is mildly bullish, but the recent performance suggests caution.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Company has a low Debt to Equity ratio (avg) at times

 
2

Poor long term growth as Operating profit has grown by an annual rate 9.68% of over the last 5 years

 
3

Positive results in Jul 25

4

With ROCE of 9.65%, it has a attractive valuation with a 1.95 Enterprise value to Capital Employed

5

High Institutional Holdings at 86.93%

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 119,277 Million (Large Cap)

stock-summary
P/E

21.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

3.08%

stock-summary
Debt Equity

0.43

stock-summary
Return on Equity

11.60%

stock-summary
Price to Book

2.49

Revenue and Profits:
Net Sales:
8,578 Million
(Quarterly Results - Jul 2025)
Net Profit:
1,047 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
10.56%
0%
10.56%
6 Months
19.23%
0%
19.23%
1 Year
18.99%
0%
18.99%
2 Years
27.5%
0%
27.5%
3 Years
28.1%
0%
28.1%
4 Years
-4.57%
0%
-4.57%
5 Years
-9.32%
0%
-9.32%

Medtronic Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Medtronic Plc Hits New 52-Week High of USD 103.70

Medtronic Plc Hits New 52-Week High of USD 103.70

Medtronic Plc achieved a new 52-week high of USD 103.70 on November 24, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a notable increase over the past year, with solid financial metrics including a P/E ratio of 21.00 and a dividend yield of 3.08%.

Read More
Medtronic Plc Experiences Revision in Its Stock Evaluation Amid Strong Financial Performance

Medtronic Plc Experiences Revision in Its Stock Evaluation Amid Strong Financial Performance

Medtronic Plc has reported strong financial results for the quarter ending July 2025, showcasing an operating cash flow of USD 7,146 million and a return on capital employed of 9.72%. The company also achieved a dividend per share of USD 5.57 and a high inventory turnover ratio of 2.43 times, despite facing challenges with a high debt-equity ratio of 42.78%.

Read More
Medtronic Hits New 52-Week High of $102.59, Showcasing Strong Growth

Medtronic Hits New 52-Week High of $102.59, Showcasing Strong Growth

Medtronic Plc achieved a new 52-week high of USD 102.59 on November 19, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a 20.69% increase over the past year, with a market capitalization of USD 119,277 million and a dividend yield of 3.08%.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
4.14%
EBIT Growth (5y)
9.68%
EBIT to Interest (avg)
8.66
Debt to EBITDA (avg)
1.92
Net Debt to Equity (avg)
0.41
Sales to Capital Employed (avg)
0.43
Tax Ratio
16.65%
Dividend Payout Ratio
77.47%
Pledged Shares
0
Institutional Holding
86.93%
ROCE (avg)
8.75%
ROE (avg)
9.79%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
2.34
EV to EBIT
20.20
EV to EBITDA
15.42
EV to Capital Employed
1.95
EV to Sales
3.93
PEG Ratio
1.00
Dividend Yield
3.29%
ROCE (Latest)
9.65%
ROE (Latest)
11.03%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Apr 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 244 Schemes (34.06%)

Foreign Institutions

Held by 526 Foreign Institutions (19.93%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jul'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jul 2025 is 8.38% vs 2.77% in Jul 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jul 2025 is -0.10% vs 31.49% in Jul 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jul'25",
        "Jul'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8,578.00",
          "val2": "7,915.00",
          "chgp": "8.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,265.00",
          "val2": "2,025.00",
          "chgp": "11.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "176.00",
          "val2": "167.00",
          "chgp": "5.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-268.00",
          "val2": "-156.00",
          "chgp": "-71.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,047.00",
          "val2": "1,048.00",
          "chgp": "-0.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "176.80%",
          "val2": "172.20%",
          "chgp": "0.46%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Apr'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Apr 2025 is 3.62% vs 3.64% in Apr 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Apr 2025 is 26.67% vs -2.11% in Apr 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Apr'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "33,537.00",
          "val2": "32,364.00",
          "chgp": "3.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "9,054.00",
          "val2": "8,379.00",
          "chgp": "8.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "729.00",
          "val2": "719.00",
          "chgp": "1.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-879.00",
          "val2": "-1,028.00",
          "chgp": "14.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "4,692.00",
          "val2": "3,704.00",
          "chgp": "26.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "184.70%",
          "val2": "177.10%",
          "chgp": "0.76%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jul'25 - YoYstock-summary
Jul'25
Jul'24
Change(%)
Net Sales
8,578.00
7,915.00
8.38%
Operating Profit (PBDIT) excl Other Income
2,265.00
2,025.00
11.85%
Interest
176.00
167.00
5.39%
Exceptional Items
-268.00
-156.00
-71.79%
Consolidate Net Profit
1,047.00
1,048.00
-0.10%
Operating Profit Margin (Excl OI)
176.80%
172.20%
0.46%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jul 2025 is 8.38% vs 2.77% in Jul 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jul 2025 is -0.10% vs 31.49% in Jul 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Apr'25stock-summary
Apr'25
Apr'24
Change(%)
Net Sales
33,537.00
32,364.00
3.62%
Operating Profit (PBDIT) excl Other Income
9,054.00
8,379.00
8.06%
Interest
729.00
719.00
1.39%
Exceptional Items
-879.00
-1,028.00
14.49%
Consolidate Net Profit
4,692.00
3,704.00
26.67%
Operating Profit Margin (Excl OI)
184.70%
177.10%
0.76%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Apr 2025 is 3.62% vs 3.64% in Apr 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Apr 2025 is 26.67% vs -2.11% in Apr 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About Medtronic Plc stock-summary
stock-summary
Medtronic Plc
Pharmaceuticals & Biotechnology
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc.
Company Coordinates stock-summary
Company Details
20 On Hatch, Hatch Street Lower , DUBLIN None : 2
stock-summary
Tel: 353 1 43817001 763 5052692
stock-summary
http://www.medtronic.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."